Cardioprotective Effects of a Selective B2 Receptor Agonist of Bradykinin Post-Acute Myocardial Infarct

被引:44
作者
Marketou, Maria [1 ]
Kintsurashvili, Ekaterina [1 ,2 ]
Papanicolaou, Kyriakos N. [3 ]
Lucero, Hector A. [1 ,2 ]
Gavras, Irene [1 ]
Gavras, Haralambos [1 ,2 ]
机构
[1] Boston Univ, Sch Med, Hypertens & Atherosclerosis Sect, Dept Med, Boston, MA 02118 USA
[2] Alapis Res Labs Inc, Boston, MA USA
[3] Boston Univ, Whitaker Cardiovasc Inst, Mol Cardiol Unit, Boston, MA 02215 USA
关键词
blood pressure; bradykinin analogue; cardiac function; cardiac remodeling; hypertension; myocardial ischemia; CONVERTING ENZYME-INHIBITION; INSULIN SENSITIVITY; BLOOD-PRESSURE; ANGIOTENSIN; KININS; ISCHEMIA; HEART; HYPERTENSION; BLOCKADE; B1;
D O I
10.1038/ajh.2010.20
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND The cardioprotective benefits of bradykinin are attributable to activation of its B-2 receptor (B2R)-mediated actions and abolished by B2R antagonists. The current experiments evaluated the cardioprotective potential of a potent, long-acting B2R-selective agonist peptide analogue of bradykinin, the compound NG291. METHODS We compared the extent of cardiac tissue damage and remodeling and expression pattern of selected genes in mice submitted to acute myocardial infarct (MI) and treated for 1 week with either NG291 [Hyp(3),Thi(5),(N)Chg(7),Thi(8)]-bradykinin or with saline delivered via osmotic minipump. RESULTS Active treatment resulted in better ejection fraction (EF) 69 +/- 1% vs. 61 +/- 3.1% (P = 0.01), (vs. 85 +/- 1.3% in sham-operated controls), fractional shortening (FS) 38 +/- 4% vs. 32 +/- 8% (NS) (vs. 53 +/- 1.2 in sham-operated controls), and fewer markers of myocyte apoptosis (TUNEL-positive nuclei 4.9 +/- 1.1% vs. 9.7 +/- 0.03%, P = 0.03). Systolic blood pressure (SBP) at end point was normal at 110 +/- 4.2 in actively treated mice, but tended to be lower at 104 +/- 4.7 mm Hg in saline controls with decreased cardiac systolic capacity. Expression patterns of selected genes to factors related to tissue injury, inflammation, and metabolism (i.e., the B1R, B2R, endothelial nitric oxide synthase (eNOS),TNF-alpha, cardiomyopathy-associated 3 (Cmya3), and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4)) showed that acute MI induced significant upregulation of these genes, and active treatment prevented or attenuated this upregulation, whereas the B2R agonist itself produced no difference in the myocardium of sham-operated mice. CONCLUSIONS Treatment with a selective B2R agonist initiated at the time of induction of acute MI in mice had a beneficial effect on cardiac function, tissue remodeling, and inflammation-related tissue gene expression, which may explain its structural and functional benefits.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 46 条
[1]   Salt-sensitive hypertension in bradykinin B-2 receptor knockout mice [J].
Alfie, ME ;
Yang, XP ;
Hess, F ;
Carretero, OA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 224 (03) :625-630
[2]   Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor [J].
Belanger, Simon ;
Bovenzi, Veronica ;
Cote, Jerome ;
Neugebauer, Witold ;
Amblard, Muriel ;
Martinez, Jean ;
Lammek, Bernard ;
Savard, Martin ;
Gobeil, Fernand, Jr. .
PEPTIDES, 2009, 30 (04) :777-787
[3]   VASODEPRESSOR ROLE OF ENDOGENOUS BRADYKININ ASSESSED BY A BRADYKININ ANTAGONIST [J].
BENETOS, A ;
GAVRAS, H ;
STEWART, JM ;
VAVREK, RJ ;
HATINOGLOU, S ;
GAVRAS, I .
HYPERTENSION, 1986, 8 (11) :971-974
[4]   A novel gene (Cmya3) induced in the heart by angiotensin II-dependent but not salt-dependent hypertension in mice [J].
Duka, A ;
Schwartz, F ;
Duka, I ;
Johns, C ;
Melista, E ;
Gavras, I ;
Gavras, H .
AMERICAN JOURNAL OF HYPERTENSION, 2006, 19 (03) :275-281
[5]   Angiotensin-converting enzyme inhibition after experimental myocardial infarct [J].
Duka, Arvi ;
Kintsurashvili, Ekaterina ;
Duka, Irena ;
Ona, Deborah ;
Hopkins, Teresa A. ;
Bader, Michael ;
Gavras, Irene ;
Gavras, Haralambos .
HYPERTENSION, 2008, 51 (05) :1352-1357
[6]   Role of the B2 receptor of bradykinin in insulin sensitivity [J].
Duka, I ;
Shenouda, S ;
Johns, C ;
Kintsurashvili, E ;
Gavras, I ;
Gavras, H .
HYPERTENSION, 2001, 38 (06) :1355-1360
[7]   The ACE and I:: how ACE inhibitors came to be [J].
Erdos, Ervin G. .
FASEB JOURNAL, 2006, 20 (08) :1034-1038
[8]   Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation [J].
Faussner, A ;
Bathon, JM ;
Proud, D .
IMMUNOPHARMACOLOGY, 1999, 45 (1-3) :13-20
[9]  
Feuvray D, 2008, DIABETES METAB, V34, pS3, DOI 10.1016/S1262-3636(08)70096-X
[10]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND THE HEART [J].
GAVRAS, H .
HYPERTENSION, 1994, 23 (06) :813-818